Mirati up on Amgen’s KRAS inhibitor data

Mirati Therapeutics (MRTX +32.4%) is up on over 40% higher volume in apparent response to Phase 1 data on Amgen’s KRAS^G12C inhibitor AMG 510 presented at ASCO in Chicago.

Preliminary results showed only partial responses in five of 10 evaluable patients.

Investors appear to perceive the somewhat underwhelming data as a positive for Mirati’s KRAS^G12C inhibitor MRTX849, currently in IND-enabling studies.

#ASCO19

https://seekingalpha.com/news/3468579-mirati-32-percent-amgens-kras-inhibitor-data